NCT01114256终止不适用
FNA Tumor Sampling for CD137 Modulation: A Pilot Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 83
- 试验地点
- 1
- 主要终点
- evaluation of change in CD137 positive NK cells in blood & tumors in response to therapeutic moAbs
研究概览
简要总结
The purpose of this study is to better understand the biology of the body's immune response to monoclonal antibody therapy for cancer. Your health information will be used to identify your tissues. The tissue we obtain may be useful for research or education, resulting in new drugs, therapies or diagnostic procedures.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
evaluation of change in CD137 positive NK cells in blood & tumors in response to therapeutic moAbs
时间窗: 12 months
次要结局
- Evaluation of activation status of CD137 positive NK cells(12 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic MelanomaMelanomaNCT03356470University of Wisconsin, Madison5
已完成
2 期
A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute ExacerbationPulmonary Disease, Chronic ObstructiveNCT02522299GlaxoSmithKline44
已完成
1 期
177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid TumorsKidney CancerHead and Neck CancerBreast CancerColorectal CancerNon-small Cell Lung CancerGliomasOvarian CancerEsophageal CancerPancreatic CancerNCT00967577Weill Medical College of Cornell University20
终止
不适用
An Experimental Medicine Clinical Study to Compare Peripheral Immune System From Subjects Without Cancer Diagnosis and Patients With Solid Tumours.Immune SystemNCT05133128Servier36
撤回
1 期
Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic MalignancyNon-Hodgkin's LymphomaMultiple MyelomaHodgkin LymphomaChronic Myelogenous LeukemiaNCT01452334Bristol-Myers Squibb